1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents2
List of Tables 4
List of Figures 5
Introduction 7
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
BioMarin Pharmaceutical Inc. 32
Clinical Trial Overview of BioMarin Pharmaceutical Inc. 32
Sanofi 33
Clinical Trial Overview of Sanofi 33
ReGenX Biosciences, LLC 34
Clinical Trial Overview of ReGenX Biosciences, LLC 34
Medical Resources International Pte Ltd 35
Clinical Trial Overview of Medical Resources International Pte Ltd 35
Cytomedix, Inc. 36
Clinical Trial Overview of Cytomedix, Inc. 36
Clinical Trial Overview of Top Institutes / Government 37
University of Minnesota 37
Clinical Trial Overview of University of Minnesota 37
Masonic Cancer Center 38
Clinical Trial Overview of Masonic Cancer Center 38
Greenwood Genetic Center 39
Clinical Trial Overview of Greenwood Genetic Center 39
The University of Chicago 40
Clinical Trial Overview of The University of Chicago 40
University of Rostock 41
Clinical Trial Overview of University of Rostock 41
Clinical and Translational Science Institute 42
Clinical Trial Overview of Clinical and Translational Science Institute 42
Fairview University Medical Center 43
Clinical Trial Overview of Fairview University Medical Center 43
New York Medical College 44
Clinical Trial Overview of New York Medical College 44
Tehran University of Medical Sciences 45
Clinical Trial Overview of Tehran University of Medical Sciences 45
Five Key Clinical Profiles 46
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Europe, Top Countries, 2014* 12
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by BioMarin Pharmaceutical Inc., 2014* 32
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 33
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by ReGenX Biosciences, LLC, 2014* 34
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Resources International Pte Ltd, 2014* 35
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 36
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 37
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 38
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Greenwood Genetic Center, 2014* 39
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 40
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 41
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Clinical and Translational Science Institute, 2014* 42
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014* 43
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 44
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 45

List of Figures
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 12
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5 650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

  • $ 4 700
  • Industry report
  • May 2016
  • by Grand View Research

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key ...

Global Clinical Trial Support Services Market – 2015-2020

Global Clinical Trial Support Services Market – 2015-2020

  • $ 4 250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The Global Clinical Trial Support Services Market is estimated to be $ xx billion for the year 2015 to reach $ xx billion by the year 2020. The CAGR with which market is growing is anticipated to be x.x%. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.